TORONTO, Nov. 29, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS.TO), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Dr. Kyle Dempsey has been appointed to the board of directors of the Company (the "Board") as an independent director. Dr. Dempsey is a partner at MVM Partners ("MVM"), a healthcare focused private equity fund based in Boston, Massachusetts and London, UK.
Read more at newswire.caHLS Therapeutics Announces Board Appointment
Newswire.ca - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Semiconductor%20Chip%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)
